FOXO4 is localized within the promyelocytic leukemia body in senescent cells and interacts with p53, inhibiting its nuclear exclusion 34
Prevention of lipohypertrophy: Repeated injections at the exact same spot can cause thickening and hardening of subcutaneous fat tissue (lipohypertrophy)
In 2024, FDA issued warning letters to companies including Prime Peptides, Summit Research Peptides, SwissChems, Xcel Research, and Veronvy for marketing unapproved new drugs for human use
Precision lipidology offers a practical path toward improved risk assessment and individualized therapy, but successful adoption will require standardization, clinician education, equitable access, appropriate reimbursement, and outcome-driven implementation